PFE - 2024 Marks a New Era Of Pharmaceutical Innovation | Benzinga
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned to fighting cancer, the one battle that pharma never seems to win. Moderna ended 2023 by delivering good news regarding its cancer vaccine and Pfizer received approval to buy the cancer drug maker Seagan and execute its plan of creating a new oncology division that will battle cancer at the speed of science. But, the oncology front got strengthened by a smallermolecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed N.V. (NASDAQ: MYNZ) and its flagship product ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer (CRC).
Mainz Biomed made significant progress in the battle against CRC last year, promising to bring to the market the most advanced at-home diagnostic screening tool.
Mainz Biomed made significant progress in the battle against CRC last year, promising to bring to the market the most advanced at-home diagnostic screening tool.
Mainz Biomed just issued a report that summarizes its key product and commercial development in 2023. Its CRC screening test that is based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples is already marketed across Europe with the company continuing to expand its international commercialization. During 2023, Mainz Biomed reported groundbreaking results both from its European ColoFuture and U.S. eAArly DETECT studies. ColoFuture reported sensitivity for colorectal ...